federal_register: 2022-23866
This data as json
| document_number | title | type | abstract | publication_date | pub_year | pub_month | html_url | pdf_url | agency_names | agency_ids | excerpts |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-23866 | Cross Labeling Oncology Drugs in Combination Regimens; Guidance for Industry; Availability | Notice | The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Cross Labeling Oncology Drugs in Combination Regimens." This guidance describes FDA's current recommendations on including relevant information in labeling for oncology drugs approved for use in combination regimens. This guidance finalizes the draft guidance of the same title issued on November 20, 2020. | 2022-11-03 | 2022 | 11 | https://www.federalregister.gov/documents/2022/11/03/2022-23866/cross-labeling-oncology-drugs-in-combination-regimens-guidance-for-industry-availability | https://www.govinfo.gov/content/pkg/FR-2022-11-03/pdf/2022-23866.pdf | Health and Human Services Department; Food and Drug Administration | 221,199 | The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Cross Labeling Oncology Drugs in Combination Regimens." This guidance describes FDA's current recommendations on including... |